

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



TFIIIC110 (R95) Peptide

Cat No.: BS2107P

Background

RNA polymerase (pol) III synthesizes tRNA, 5s rRNA, 7SL RNA and U6 snRNA and is overexpressed in many transformed cell lines and tumors in vivo, since cells must duplicate its protein components before division. Therefore, in order to maintain rapid growth, cells must produce a high level of Pol III transcribed RNA, which requires the presence of the TFIIB and TFIIC2 transcription factor complexes. The TFIIC2 complex is composed of five subunits, TFIIC220, TFIIC110, TFIIC102, TFIIC90 and TFIIC63, that are overexpressed in adenovirus transformed cells as well as in malignant cells in vivo, such as ovarian carcinomas. TFIIC2 recruits RNA pol III and TFIIB to promoter elements and may be a key component in the deregulation of malignant cells. The TFIIB complex includes the TATA-binding protein (TBP), TFIIB-related factor 1 (BRF1) and TFIIB", the expression of which are also upregulated in transformed cells. In many carcinomas, the tumor suppressors retinoblastoma (RB) and p53 are inactivated, which affects their ability to bind and inactivate the function of TFIIB.

Swiss-Prot

Q8WUA4

Applications

Blocking

Specificity

This peptide can be used with studies using BS2107 TFIIC110 (R95) pAb.

Purification & Purity

Synthetic peptide TFIIC110 (R95). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.